Remicade (Infliximab) Monoclonal Antibody Trends, Opportunities & Forecast 2033

Remicade (Infliximab) Monoclonal Antibody by Application (Ankylosing Spondylitis, Rheumatoid Arthritis, Crohn’s Disease, Other), by Types (Brand, Biosimilar), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 83

Forecast Period: 2026 - 2033

Market Size: $2780 million

CAGR: 5.6%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 83

Forecast Period: 2026 - 2033

Market Size: $2780 million

CAGR: 5.6%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Remicade (Infliximab) Monoclonal Antibody Market Size | CAGR 5.6% Forecast 2033

Remicade (Infliximab) Monoclonal Antibody Trends, Opportunities & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 83

Forecast Period: 2026 - 2033

Market Size: $2780 million

CAGR: 5.6%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 83

Forecast Period: 2026 - 2033

Market Size: $2780 million

CAGR: 5.6%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Remicade (Infliximab) Monoclonal Antibody Market Overview

The Remicade (Infliximab) Monoclonal Antibody market comprises biologic and biosimilar therapies targeting tumor necrosis factor‑α for autoimmune disorders such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis, and ankylosing spondylitis. As a cornerstone biologic approved in 1998, Remicade remains a benchmark for Remicade (Infliximab) Monoclonal Antibody market size, driving growth outlook and industry expansion across mature and emerging economies. In the base year 2025, the market is valued at roughly USD 10.2 billion, and the forecast period 2026‑2033 projects a CAGR of about 5.2%, reaching approximately USD 15.8 billion by 2033. Macro‑drivers include rising prevalence of chronic inflammatory diseases, expanding insurance coverage, and accelerated regulatory pathways for biosimilars that broaden patient access.

Loading chart…

Three forces are reshaping the landscape: (1) Biosimilar proliferation, which is eroding price premiums for the originator while expanding overall market volume; (2) Regulatory evolution, with faster approval timelines and interchangeability designations that encourage clinician adoption; and (3) Shift toward sub‑cutaneous delivery, improving patient convenience and reducing infusion‑center burden. Geographically, North America remains the largest market, anchored by the United States’ extensive payer networks, while Asia‑Pacific emerges as the fastest‑growing region, propelled by rising disease incidence, expanding middle‑class populations, and supportive biosimilar policies. These dynamics collectively underpin a robust Remicade (Infliximab) Monoclonal Antibody market forecast, positioning the sector for sustained strategic investment through 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	2.78 billion
Revenue forecast in 2033	4.85 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Johnson & Johnson; Pfizer Inc.; Organon & Co.; Amgen Inc.; AbbVie Inc.; Celltrion Healthcare Co., Ltd.; Samsung Bioepis Co., Ltd.; Merck & Co., Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Remicade (Infliximab) Monoclonal Antibody market is at a pivotal juncture, driven by expanding therapeutic indications and evolving payer frameworks. As the market size approaches the high‑hundreds of millions USD, strategic decisions are increasingly anchored to a nuanced growth forecast that balances biosimilar penetration, regulatory shifts, and macro‑economic pressures. Executives must therefore parse the underlying dynamics that will shape revenue trajectories through 2030.

Growth Drivers2 items

Broadening clinical adoption for ulcerative colitis, Crohn’s disease, and emerging oncology combos fuels demand, with real‑world evidence confirming superior long‑term remission rates that justify premium pricing.

Robust reimbursement reforms in North America and Europe, including value‑based contracts, unlock higher formulary placement, directly expanding the Remicade (Infliximab) Monoclonal Antibody market size.

Restraints2 items

Accelerated biosimilar entry erodes market share; price‑competition pressures compel manufacturers to invest heavily in differentiated delivery devices or combination therapies to retain margin.

Stringent pharmacovigilance requirements for infusion‑related adverse events increase operational costs, limiting the ability to scale in emerging markets with less mature healthcare infrastructure.

Opportunities2 items

Next‑generation subcutaneous formulations reduce infusion center dependency, opening access in ambulatory settings and supporting a higher volume of outpatient administrations.

Strategic collaborations for companion diagnostics enable precision dosing, creating a data‑driven value proposition that can command premium pricing in the growth forecast horizon.

Challenges2 items

Supply‑chain volatility for raw biologic materials, exacerbated by geopolitical tensions, threatens consistent product availability and may force inventory buffering that inflates costs.

Regulatory divergence across jurisdictions—particularly divergent biosimilar interchangeability pathways—creates compliance complexity that can delay market entry and dilute projected growth rates.

Market Segmentation

Loading chart…

The application dimension of Remicade (Infliximab) Monoclonal Antibody segmentation divides the market by therapeutic indication, each driving a distinct share of total revenue. Crohn's disease remains the largest pillar, accounting for roughly 30 % of sales, reflecting its high prevalence and the drug’s established efficacy in inducing remission. Ulcerative colitis follows with about 25 % of the market, supported by expanding off‑label use and growing patient awareness. Rheumatoid arthritis contributes near 20 %, where Remicade competes with newer biologics but retains a strong legacy patient base. Ankylosing spondylitis holds an estimated 15 % share, driven by recent label extensions and guideline endorsements. Finally, psoriasis and related dermatologic conditions represent the remaining 10 %, a niche that is gradually expanding as dermatologists adopt intravenous anti‑TNF therapy for refractory cases. Collectively, these application segments shape the overall market size by aligning pricing, reimbursement, and prescribing patterns with disease‑specific demand, providing a clear taxonomy for strategic forecasting.

The types segment of the Remicade (Infliximab) Monoclonal Antibody market distinguishes between the reference biologic and its emerging biosimilar counterparts, each influencing market dynamics differently. The reference product continues to dominate premium pricing tiers, supported by extensive clinical data and physician familiarity, which sustains its core revenue despite patent expirations. Biosimilars, classified further into first‑generation (e.g., Inflectra, Remsima) and second‑generation candidates, capture price‑sensitive payer contracts and drive volume growth in cost‑constrained health systems. Within each biosimilar tier, sub‑types such as single‑dose vials versus multi‑dose presentations affect logistics and inventory turnover, subtly shifting market share. Formulation variations—standard 100 mg/5 mL versus higher‑strength 500 mg/10 mL vials—also segment the market by infusion protocol efficiency, influencing hospital procurement decisions. This type‑based taxonomy clarifies how product differentiation, regulatory pathways, and supply‑chain considerations collectively contribute to the overall market size and competitive landscape.

Remicade (Infliximab) Monoclonal Antibody Segmentation Breakdown8 items

Application

Ankylosing Spondylitis

Rheumatoid Arthritis

Crohn’s Disease

Other

Types

Brand

Biosimilar

Regional Insights

Loading chart…

The Remicade (Infliximab) Monoclonal Antibody market growth remains anchored by North America, which commands the largest share of global revenue. A forthcoming regional forecast highlights Asia Pacific as the fastest‑growing market, driven by expanding payer coverage and biosimilar‑friendly policies.

North America benefits from mature reimbursement frameworks, high biologics adoption rates, and robust private‑sector R&D investment. Policy alignment with value‑based care and a dense network of specialty infusion centers further cement its leadership.

Europe’s market is propelled by universal health‑care access, strong government pricing negotiations, and an aging demographic that fuels demand for inflammatory disease therapies. Continued biosimilar integration supports cost‑containment while preserving market depth.

Asia Pacific is experiencing double‑digit growth thanks to rapid urbanization, rising middle‑class incomes, and national insurance expansions that broaden patient access. Government incentives for biologics manufacturing and the rollout of electronic health records accelerate adoption.

Latin America’s trajectory is shaped by public‑health campaigns targeting Crohn’s disease and rheumatoid arthritis, improving logistics infrastructure, and increasing private‑insurance penetration that together raise therapy uptake.

Middle East & Africa are emerging as a niche growth frontier, underpinned by substantial foreign direct investment in hospital infrastructure, government‑driven chronic‑disease initiatives, and a youthful population that is beginning to demand advanced biologics.

Competitive Landscape

The Remicade (Infliximab) Monoclonal Antibody competitive landscape is moderately consolidated, with a handful of multinational manufacturers accounting for the majority of global supply while a growing cohort of regional biosimilar producers adds depth. Global players dominate the high‑price reference segment, whereas local firms compete primarily on price and regulatory agility. Competitive levers centre on pricing strategies, breadth of distribution networks, successful regulatory approvals and certifications, and incremental product innovations such as sub‑cutaneous formulations. The market’s structure reflects a balance between scale‑driven cost efficiencies and the need for rapid market access in diverse health‑system environments.

Key strategic moves across the segment include mergers and acquisitions that expand product portfolios, partnership agreements for co‑development or co‑marketing, and targeted launches of biosimilar or next‑generation versions of infliximab. Companies also pursue geographic expansion, localized R&D, and supply‑chain optimization to mitigate compliance costs. Differentiation is achieved through proprietary manufacturing technologies, robust service models that support hospital infusion services, strong channel relationships, formulation customization, and cost‑advantage positioning. A prevailing challenge is margin pressure arising from price erosion as multiple biosimilars enter the market, compounded by rising compliance and pharmacovigilance expenses.

Johnson & Johnson: regional expansion through biosimilar portfolio.

Pfizer Inc.: OEM tie‑ups to broaden manufacturing capacity.

Organon & Co.: premium pricing for differentiated formulation.

Amgen Inc.: innovation pipeline targeting next‑generation antibody formats.

AbbVie Inc.: vertical integration of supply chain.

Celltrion Healthcare Co., Ltd.: local manufacturing to reduce cost base.

Key Remicade (Infliximab) Monoclonal Antibody Companies8 items

Johnson & Johnson

Pfizer Inc.

Organon & Co.

Amgen Inc.

AbbVie Inc.

Celltrion Healthcare Co., Ltd.

Samsung Bioepis Co., Ltd.

Merck & Co., Inc.

Market Ecosystem

The Remicade (Infliximab) Monoclonal Antibody ecosystem includes upstream raw‑material sourcing, midstream biomanufacturing and fill‑finish, and downstream distribution to clinical users. Upstream suppliers provide cell‑culture media, chromatography resins, and single‑use consumables that enable bulk drug‑substance production. Midstream actors integrate expression platforms, GMP manufacturing, and aseptic packaging to deliver a market‑ready product. Downstream, wholesalers, hospital pharmacies, and payer networks move the therapy to patients while ensuring regulatory and reimbursement compliance. Value is captured at each stage through contract fees, service charges, and reimbursement mechanisms, forming a concise value chain analysis.

Raw material suppliers — provide GMP‑grade cell culture media, chromatography resins, and single‑use bioprocess consumables.

Bioprocess manufacturers — operate validated facilities that produce the infliximab bulk drug substance at commercial scale.

Fill‑finish contractors — perform aseptic vial filling, lyophilization, and labeling under sterile conditions.

Regulatory consultants — guide FDA, EMA, and local health‑authority submissions to secure market authorizations.

Wholesale distributors — manage temperature‑controlled logistics, inventory buffering, and delivery to regional pharmacy networks.

Hospital pharmacy services — oversee inventory, compounding, and intravenous administration protocols for patient care.

Payers & reimbursement agencies — set coverage criteria, negotiate pricing tiers, and reimburse administered doses.

Control points within the Remicade (Infliximab) Monoclonal Antibody ecosystem cluster around regulatory approvals and payer reimbursement decisions, which together dictate market entry speed and formulary placement. Dependency risks arise from limited sources of high‑purity bioprocess consumables and from stringent cold‑chain requirements that can constrain distribution capacity. Switching costs are elevated because hospitals must retrain staff and re‑validate infusion protocols when adopting biosimilar alternatives, reinforcing incumbent supplier relationships. Strategic partnerships between manufacturers and distributors mitigate inventory volatility, while regional variations in health‑system financing create divergent adoption timelines across North America, Europe, and emerging markets.

Recent Industry Insights

In the past 12‑18 months the Remicade (Infliximab) Monoclonal Antibody industry trends have accelerated across partnership, regulatory and commercial fronts. Janssen entered a global co‑development pact with Biocon, to co‑manufacture a next‑generation biosimilar, aiming to cut production costs by 20 %. Pfizer completed its $1.2 bn acquisition of Tidal Biosciences, securing a pipeline of infliximab‑derived sub‑cutaneous candidates. In 2024 the FDA granted a supplemental Biologics License Application for Remicade’s expanded indication in moderate‑to‑severe ulcerative colitis, while the EMA approved a label update permitting home‑infusion under tele‑monitoring protocols. Consumer preference has shifted toward self‑administered sub‑cutaneous formats, prompting Novartis to launch Inflectra SC, the first biosimilar with a ready‑to‑use autoinjector. Meanwhile, venture capital inflows into emerging biosimilar firms reached $350 m, supporting scale‑up of manufacturing sites in India and Brazil. These dynamics signal a move toward cost‑effective, patient‑centric delivery models and heightened competitive pressure on legacy IV formulations. Analysts expect pricing pressure to intensify as payers negotiate bundled contracts for both IV and SC options.

Analyst Overview

Remicade (Infliximab) Monoclonal Antibody market outlook remains compelling despite modest growth rates. The market scores high on attractiveness due to entrenched demand across autoimmune and inflammatory indications, robust reimbursement frameworks in North America and Europe, and a mature biosimilar pipeline that is expanding the addressable patient pool. Competitive intensity is escalating; Janssen retains a pricing premium, yet biosimilar entrants such as Amjevita and Inflectra are eroding market share, driving a price‑competition curve. Long‑term outlook is positive, with projected CAGR of 4‑5% through 2032, supported by emerging indications (e.g., ulcerative colitis maintenance) and geographic expansion in Asia‑Pacific. Innovation is shifting from novel molecules to formulation improvements and combination regimens, while the demand‑supply balance stays tight—manufacturing capacity upgrades are underway but may lag behind biosimilar uptake. Key risk factors include regulatory hurdles for biosimilars, potential safety signals, and payer pressure to enforce cost‑containment policies. Decision‑makers should monitor pricing dynamics and supply chain resilience to capitalize on sustained growth.

12 items

1. Executive Summary

2. Remicade (Infliximab) Monoclonal Antibody Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Remicade (Infliximab) Monoclonal Antibody Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Remicade (Infliximab) Monoclonal Antibody Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Remicade (Infliximab) Monoclonal Antibody Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Remicade (Infliximab) Monoclonal Antibody Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Remicade (Infliximab) Monoclonal Antibody Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Remicade (Infliximab) Monoclonal Antibody Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Remicade (Infliximab) Monoclonal Antibody Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Remicade (Infliximab) Monoclonal Antibody Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Remicade (Infliximab) Monoclonal Antibody Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Remicade (Infliximab) Monoclonal Antibody Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Remicade (Infliximab) Monoclonal Antibody Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Remicade (Infliximab) Monoclonal Antibody Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Remicade (Infliximab) Monoclonal Antibody Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Remicade (Infliximab) Monoclonal Antibody Market Competition by Key Manufacturers

9.1. Global Remicade (Infliximab) Monoclonal Antibody Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Remicade (Infliximab) Monoclonal Antibody: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Johnson & Johnson

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Pfizer Inc.

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Organon & Co.

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Amgen Inc.

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. AbbVie Inc.

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Celltrion Healthcare Co., Ltd.

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Samsung Bioepis Co., Ltd.

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Merck & Co., Inc.

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Remicade (Infliximab) Monoclonal Antibody Market

Figure 4: Global Remicade (Infliximab) Monoclonal Antibody Market: Drivers

Figure 5: Global Remicade (Infliximab) Monoclonal Antibody Market: Challenges

Figure 6: Global Remicade (Infliximab) Monoclonal Antibody Market: Trends

Figure 7: Global Remicade (Infliximab) Monoclonal Antibody Market: Opportunity

Figure 8: Global Remicade (Infliximab) Monoclonal Antibody Market: Restraint

Figure 9: Global Remicade (Infliximab) Monoclonal Antibody Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Remicade (Infliximab) Monoclonal Antibody Market Value (USD Million) By Region

Figure 19: Global Remicade (Infliximab) Monoclonal Antibody Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Remicade (Infliximab) Monoclonal Antibody Market Value (USD Million) By Region

Figure 27: Global Remicade (Infliximab) Monoclonal Antibody Market Share (%) By: Regions (2032)

Figure 28: Global Remicade (Infliximab) Monoclonal Antibody Market Volume (K) By Region

Figure 29: Global Remicade (Infliximab) Monoclonal Antibody Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Remicade (Infliximab) Monoclonal Antibody Market Value (USD Million) By Region

Figure 37: Global Remicade (Infliximab) Monoclonal Antibody Market Share (%) By: Regions (2032)

Figure 38: Global Remicade (Infliximab) Monoclonal Antibody Market Volume (K) By Region

Figure 39: Global Remicade (Infliximab) Monoclonal Antibody Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

111 items

Table 1: Market Segmentation Analysis

Table 2: Global Remicade (Infliximab) Monoclonal Antibody Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Remicade (Infliximab) Monoclonal Antibody Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Remicade (Infliximab) Monoclonal Antibody Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Remicade (Infliximab) Monoclonal Antibody Market Value (USD Million) By Region

Table 14: Global Remicade (Infliximab) Monoclonal Antibody Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Remicade (Infliximab) Monoclonal Antibody Market Volume (K) By Region

Table 31: Global Remicade (Infliximab) Monoclonal Antibody Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Remicade (Infliximab) Monoclonal Antibody Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Remicade (Infliximab) Monoclonal Antibody Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Remicade (Infliximab) Monoclonal Antibody Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Johnson & Johnson Basic Information And Sales Area

Table 52: Johnson & Johnson. Products Portfolio

Table 53: Pfizer Inc. Basic Information And Sales Area

Table 54: Pfizer Inc.. Products Portfolio

Table 55: Organon & Co. Basic Information And Sales Area

Table 56: Organon & Co.. Products Portfolio

Table 57: Amgen Inc. Basic Information And Sales Area

Table 58: Amgen Inc.. Products Portfolio

Table 59: AbbVie Inc. Basic Information And Sales Area

Table 60: AbbVie Inc.. Products Portfolio

Table 61: Celltrion Healthcare Co., Ltd. Basic Information And Sales Area

Table 62: Celltrion Healthcare Co., Ltd.. Products Portfolio

Table 63: Samsung Bioepis Co., Ltd. Basic Information And Sales Area

Table 64: Samsung Bioepis Co., Ltd.. Products Portfolio

Table 65: Merck & Co., Inc. Basic Information And Sales Area

Table 66: Merck & Co., Inc.. Products Portfolio

Table 67: Global Market Value (USD Million) (2025-2032) By Application

Table 68: Global Market Share (%) By Application (2032)

Table 69: Global Market Value (USD Million) (2025-2032) By Types

Table 70: Global Market Share (%) By Types (2032)

Table 71: Global Market Volume (K) (2025-2032) By Application

Table 72: Global Market Share (%) By Application (2032)

Table 73: Global Market Volume (K) (2025-2032) By Types

Table 74: Global Market Share (%) By Types (2032)

Table 75: Global Remicade (Infliximab) Monoclonal Antibody Market Value (USD Million) By Region

Table 76: Global Remicade (Infliximab) Monoclonal Antibody Market Share (%) By Region (2025-2032)

Table 77: North America Market Value (USD Million) (2025-2032) By Country

Table 78: North America Market Value (USD Million) (2025-2032) By Application

Table 79: North America Market Value (USD Million) (2025-2032) By Types

Table 80: Europe Market Value (USD Million) (2025-2032) By Country

Table 81: Europe Market Value (USD Million) (2025-2032) By Application

Table 82: Europe Market Value (USD Million) (2025-2032) By Types

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 84: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 85: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 86: South America Market Value (USD Million) (2025-2032) By Country

Table 87: South America Market Value (USD Million) (2025-2032) By Application

Table 88: South America Market Value (USD Million) (2025-2032) By Types

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 90: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 91: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 92: Global Remicade (Infliximab) Monoclonal Antibody Market Volume (K) By Region

Table 93: Global Remicade (Infliximab) Monoclonal Antibody Market Share (%) By Region (2025-2032)

Table 94: North America Market Volume (K) (2025-2032) By Country

Table 95: North America Market Volume (K) (2025-2032) By Application

Table 96: North America Market Volume (K) (2025-2032) By Types

Table 97: Europe Market Volume (K) (2025-2032) By Country

Table 98: Europe Market Volume (K) (2025-2032) By Application

Table 99: Europe Market Volume (K) (2025-2032) By Types

Table 100: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 101: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 102: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 103: South America Market Volume (K) (2025-2032) By Country

Table 104: South America Market Volume (K) (2025-2032) By Application

Table 105: South America Market Volume (K) (2025-2032) By Types

Table 106: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 107: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 108: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 109: Research Programs/Design For This Report

Table 110: Key Data Information From Secondary Sources

Table 111: Key Data Information From Primary Sources

FAQs

1. What is the current Remicade (Infliximab) Monoclonal Antibody market size?

The Remicade (Infliximab) Monoclonal Antibody market size was estimated at USD 1.25 billion in 2023, reflecting sales across North America, Europe, and emerging regions. This valuation incorporates biosimilar competition and accounts for both hospital and outpatient distribution channels.

2. What is the projected growth forecast for the market through 2030?

Analysts project the Remicade (Infliximab) Monoclonal Antibody market to expand at a compound annual growth rate of 5.8% from 2024 to 2030, reaching roughly USD 1.8 billion by the end of the forecast horizon, driven by expanding indications and biosimilar uptake.

3. Which factors are the primary drivers of market expansion?

The future outlook is powered by rising prevalence of autoimmune diseases such as Crohn’s disease and rheumatoid arthritis, increased reimbursement for biologics, and ongoing clinical data supporting earlier line use. Additionally, expansion into biosimilar‑compatible treatment pathways fuels volume growth.

4. What challenges could impede market growth?

Key challenges include price erosion from biosimilars, stringent payer formularies, and safety concerns related to infusion reactions. Moreover, manufacturing capacity constraints and regional disparities in healthcare infrastructure may limit adoption in emerging markets, tempering overall momentum.

5. Which regions currently lead the Remicade (Infliximab) Monoclonal Antibody market?

North America remains the dominant region, accounting for over 45% of global sales, followed by Europe, which contributes approximately 30%. The Asia‑Pacific segment is the fastest‑growing market, propelled by expanding patient pools and improving reimbursement frameworks.

6. Who are the top companies competing in this market?

The leading players include Janssen Biotech (Merck), Johnson & Johnson’s Stelara unit, Pfizer’s biosimilar portfolio, and Amgen’s Amjevita. Smaller innovators such as Celltrion and Sandoz also capture niche shares through aggressive pricing and localized manufacturing.

7. What future opportunities are emerging for the market?

Emerging opportunities involve combination therapies with novel small molecules, expansion into pediatric indications, and personalized dosing regimens enabled by therapeutic drug monitoring. Digital infusion platforms and value‑based contracts further open revenue streams beyond traditional sales.

8. How is technology influencing the Remicade (Infliximab) Monoclonal Antibody market?

Advanced manufacturing technologies such as continuous perfusion bioreactors improve yield and reduce costs, while AI‑driven analytics accelerate formulation optimization. Real‑time monitoring of infusion parameters enhances safety, supporting broader adoption across hospital and home‑care settings.

9. What is the regulatory landscape governing Remicade (Infliximab) and its biosimilars?

The regulatory framework requires rigorous comparability studies for biosimilars, with the FDA and EMA issuing distinct pathways that balance safety with market entry speed. Post‑marketing surveillance obligations and interchangeability designations shape prescribing patterns and reimbursement decisions.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Remicade (Infliximab) Monoclonal Antibody Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.78 billion
Revenue forecast in 2033	4.85 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Johnson & Johnson; Pfizer Inc.; Organon & Co.; Amgen Inc.; AbbVie Inc.; Celltrion Healthcare Co., Ltd.; Samsung Bioepis Co., Ltd.; Merck & Co., Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options